These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19843057)

  • 21. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
    van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
    J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
    Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
    Cannon CP; Dansky HM; Davidson M; Gotto AM; Brinton EA; Gould AL; Stepanavage M; Liu SX; Shah S; Rubino J; Gibbons P; Hermanowski-Vosatka A; Binkowitz B; Mitchel Y; Barter P;
    Am Heart J; 2009 Oct; 158(4):513-519.e3. PubMed ID: 19781408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects.
    Krishna R; Stypinski D; Ali M; Garg A; Gendrano IN; Maes A; DeGroot B; Liu Y; Li S; Connolly SM; Wagner JA; Stoch SA
    Biopharm Drug Dispos; 2011 Dec; 32(9):525-9. PubMed ID: 22031172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
    Gotto AM; Kher U; Chatterjee MS; Liu Y; Li XS; Vaidya S; Cannon CP; Brinton EA; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):543-9. PubMed ID: 24737712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
    Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
    Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
    Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA; Davis K
    Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
    Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
    J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects.
    Krishna R; Gheyas F; Corr C; Cote J; Liu Y; Wagner J; Gutstein DE
    J Clin Pharmacol; 2018 Dec; 58(12):1578-1585. PubMed ID: 30029292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
    Miyares MA
    Ann Pharmacother; 2011 Jan; 45(1):84-94. PubMed ID: 21205945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice.
    Hartmann G; Kumar S; Johns D; Gheyas F; Gutstein D; Shen X; Burton A; Lederman H; Lutz R; Jackson T; Chavez-Eng C; Mitra K
    Drug Metab Dispos; 2016 Mar; 44(3):428-34. PubMed ID: 26712818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How anacetrapib inhibits the activity of the cholesteryl ester transfer protein? Perspective through atomistic simulations.
    Äijänen T; Koivuniemi A; Javanainen M; Rissanen S; Rog T; Vattulainen I
    PLoS Comput Biol; 2014 Nov; 10(11):e1003987. PubMed ID: 25412509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial.
    Metzinger MP; Saldanha S; Gulati J; Patel KV; El-Ghazali A; Deodhar S; Joshi PH; Ayers C; Rohatgi A
    J Am Heart Assoc; 2020 Dec; 9(24):e018136. PubMed ID: 33263263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
    Kumar S; Tan EY; Hartmann G; Biddle Z; Bergman AJ; Dru J; Ho JZ; Jones AN; Staskiewicz SJ; Braun MP; Karanam B; Dean DC; Gendrano IN; Graves MW; Wagner JA; Krishna R
    Drug Metab Dispos; 2010 Mar; 38(3):474-83. PubMed ID: 20016053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anacetrapib: a new weapon against dyslipidemia.
    Aperis G; Paliouras C; Tsampikaki E; Papakonstantinou N; Alivanis P
    Curr Clin Pharmacol; 2011 Nov; 6(4):227-35. PubMed ID: 22082322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical characterization of cholesteryl ester transfer protein inhibitors.
    Ranalletta M; Bierilo KK; Chen Y; Milot D; Chen Q; Tung E; Houde C; Elowe NH; Garcia-Calvo M; Porter G; Eveland S; Frantz-Wattley B; Kavana M; Addona G; Sinclair P; Sparrow C; O'Neill EA; Koblan KS; Sitlani A; Hubbard B; Fisher TS
    J Lipid Res; 2010 Sep; 51(9):2739-52. PubMed ID: 20458119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.